| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study
|
Cook, Gordon
|
|
2019
|
6 |
3 |
p. e154-e166
|
article
|
| 2 |
A new standard treatment for prevention of GvHD after HCT?
|
Choi, Sung Won
|
|
2019
|
6 |
3 |
p. e113-e114
|
article
|
| 3 |
Correction to Lancet Haematol 2018; 5: e563–98
|
|
|
2019
|
6 |
3 |
p. e121
|
article
|
| 4 |
Correction to Lancet Haematol 2019; 6: e89–99
|
|
|
2019
|
6 |
3 |
p. e121
|
article
|
| 5 |
Dose-adjusted EPOCH-R therapy in MYC-rearranged diffuse large B-cell lymphoma: not yet the standard of care
|
Casan, Joshua ML
|
|
2019
|
6 |
3 |
p. e119
|
article
|
| 6 |
Dose-adjusted EPOCH-R therapy in MYC-rearranged diffuse large B-cell lymphoma: not yet the standard of care – Authors' reply
|
Wilson, Wyndham H
|
|
2019
|
6 |
3 |
p. e120
|
article
|
| 7 |
Eltrombopag treatment during induction chemotherapy for acute myeloid leukaemia: a randomised, double-blind, phase 2 study
|
Frey, Noelle
|
|
2019
|
6 |
3 |
p. e122-e131
|
article
|
| 8 |
Eltrombopag use in higher risk myeloid cancers: fitting a square “pag” into a round hole?
|
Buckstein, Rena
|
|
2019
|
6 |
3 |
p. e111-e112
|
article
|
| 9 |
Frailty in multiple myeloma: the need for harmony to prevent doing harm
|
Zweegman, Sonja
|
|
2019
|
6 |
3 |
p. e117-e118
|
article
|
| 10 |
Health and Brexit: what lies ahead?
|
The Lancet Haematology,
|
|
2019
|
6 |
3 |
p. e110
|
article
|
| 11 |
Outcomes and risk factors of massive and submassive pulmonary embolism in children: a retrospective cohort study
|
Pelland-Marcotte, Marie-Claude
|
|
2019
|
6 |
3 |
p. e144-e153
|
article
|
| 12 |
Paediatric pulmonary embolism: a pathway to improved outcomes
|
Ignjatovic, Vera
|
|
2019
|
6 |
3 |
p. e115-e116
|
article
|
| 13 |
Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)
|
Bolaños-Meade, Javier
|
|
2019
|
6 |
3 |
p. e132-e143
|
article
|
Journal description